What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
BAN2401 may work better in genetically defined population, but with safety risks.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…